By leveraging AI and machine learning, researchers can analyze complex data sets, identify novel biomarkers, and provide more effective and tailored treatment options for cancer patients.
The more pharma companies do to become service providers in the personalized medicine era, the more they’ll succeed and the more lives they’ll help to save.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Malla, a startup that launched Wednesday, is trying to make functional, personalized medicine more accessible. Consumers can purchase a membership, which includes one-on-one video sessions with a practitioner, messaging, personalized care plans and tracking.
Oncology Ventures recently announced investments in three cancer startups — VivorCare, Gabbi and Health Universe. The fund's founding partner said each company demonstrated an ability to tackle a specific problem within the cancer care space, such as enabling earlier breast cancer diagnoses and providing personalized care plans for cancer survivors.
Optimizing drug routines allows prescribers to make more informed decisions that reduce risk and improve quality of care. The result is better outcomes for both patients and organizations.
If the medical field wants to make serious progress on the Cancer Moonshot effort, it must expand its definition of personalized medicine and explore fresh approaches to cancer prevention, according to Dr. Siddhartha Mukherjee, a Pulitzer Prize-winning author and cancer physician at Columbia University Medical Center.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
After some setbacks and delays, the FDA approved Bristol Myers Squibb’s Breyanzi for certain lymphomas. It’s the fourth CAR T treatment to win the regulatory nod and the first under a new regenerative medicine designation.
The biotechnology product development company announced the launch of its Ion Torrent Genexus System at the Association for Molecular Pathology's annual meeting.
The drug was approved along with a companion diagnostic to detect alterations in FGFR2 and FGFR3. The drug is approved for patients with locally advanced or metastatic UC who carry those mutations.
Innovations that emerge from the research will be commercialized through a joint venture between the school and Centene called the ARCH Personalized Medicine Initiative.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Biology and artificial intelligence are key aspects of precision medicine, but are wearables part of the equation? Panelists at the Connected Health Conference weighed in.
A recent study notes that widespread access to personal genetic information – without the knowledge of how to interpret results – can lead to problems ranging from misinterpretation to emotional distress.
Precision oncology is the proof of principle. It’s just a matter of time before such personalized tests and treatments become mainstream in other specialties, from rheumatology to endocrinology to psychiatric care.
The deal gives the Danish pharmaceutical company a consumer-focused technology platform to build on. In return, Glooko gains access to Novo Nordisk's extensive customer base and deep library of educational content.
Willing patients who agree to participate in research, and give samples are key to progressing precision medicine and data shows there isn't any dearth of these medical philanthropists.